Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC-201CR in Hemophilic Arthropathy
NCT02994147Phase 2Completed
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Mar 2017
- Primary completion
- Apr 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diacerein in hemophilic arthropathy (HA) (2 arms), sponsored by TWi Biotechnology, Inc. Primary endpoint: Change from baseline in IPSG (MRI) score for primary knee at 24 Weeks. Started Mar 2017; status: completed.
02
Drugs
diacerein
03
Conditions
hemophilic arthropathy (HA)
Beyond the preview
Go deeper on NCT02994147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994147.